Loading…
GRI Bio, Inc. is projected to rise to $1.63 by 2027, a +13% move from its current price of $1.44. GRI is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.39 | $1.44 | $1.49 | +0.01% |
| Aug 6 | $1.37 | $1.44 | $1.51 | +0.01% |
| Aug 7 | $1.36 | $1.44 | $1.52 | +0.02% |
| Aug 8 | $1.35 | $1.44 | $1.54 | +0.03% |
| Aug 9 | $1.34 | $1.44 | $1.55 | +0.03% |
| Aug 10 | $1.33 | $1.44 | $1.56 | +0.04% |
| Aug 11 | $1.32 | $1.44 | $1.57 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.32 | $1.44 | $1.57 | +0.05% |
| Week 2 | $1.27 | $1.44 | $1.63 | +0.10% |
| Week 3 | $1.24 | $1.44 | $1.68 | +0.14% |
| Week 4 | $1.21 | $1.44 | $1.72 | +0.19% |
| Week 5 | $1.19 | $1.44 | $1.75 | +0.24% |
| Week 6 | $1.17 | $1.44 | $1.79 | +0.29% |
| Week 7 | $1.15 | $1.44 | $1.82 | +0.33% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc.
was founded in 2009 and is based in LA Jolla, California.
GRI Bio, Inc. trades under the symbol GRI and operates within the Healthcare sector. The current price is $1.40, and the company has a market capitalization of $2.48M with a global rank of 5226.
The forecast view suggests a path of growth from the current price, with 2026 forecasted min $1.40, avg $1.40, max $1.90 and a 0% ROI. Over the following years, the average price climbs, reaching $4.33 by 2050 with a max of $8.98 and a 209.1% ROI, signaling a bullish longer-term outlook despite near-term uncertainty.
A major floor 31.0% below — a decisive break under it would weaken the trend.
The nearest floor, 4.2% below — buyers have tended to step in here.
The nearest ceiling, 36.1% above — a clean break opens room to run.
A major ceiling 81.2% above — clearing it would confirm fresh momentum.
Key GRI support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of GRI market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.42 | Buy | $1.42 | Buy |
| MA 10 | $1.45 | Sell | $1.46 | Sell |
| MA 20 | $1.56 | Sell | $1.56 | Sell |
| MA 50 | $1.86 | Sell | $1.90 | Sell |
| MA 100 | $2.13 | Sell | $4.69 | Sell |
| MA 200 | $13.35 | Sell | $418.67 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 31.82 | Neutral |
| Stoch RSI (14) | 33.71 | Neutral |
| CCI (20) | -99.89 | Neutral |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -14.81 | Sell |
| Bollinger %B (20,2) | 0.18 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -1.12 | Sell |
| Awesome (5,34) | -0.31 | Sell |
| Ultimate (7,14,28) | 31.63 | Neutral |
| Momentum (10) | -0.12 | Sell |
| Aroon Osc (25) | -100.00 | Sell |
| Hull MA (9) | 1.41 | Buy |
| ADX (14) | 29.53 | Sell |
| ATR (14) | 0.05 | Info |
The near-term technical posture is NEUTRAL. The RSI14 reads 30, suggesting room to move before overbought conditions appear.
The stock trades with a 50-day simple moving average (SMA50) of $1.93 and a 200-day simple moving average (SMA200) of $14.66, highlighting a potential gap between near-term momentum and longer-term trend.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.38 | $1.44 | $1.94 | 0% | Neutral | |
| $1.28 | $1.63 | $2.22 | +13% | Neutral | |
| $1.50 | $1.98 | $2.82 | +38% | Bullish | |
| $1.45 | $1.98 | $2.91 | +37% | Bullish | |
| $1.36 | $1.90 | $2.88 | +32% | Bullish | |
| $1.23 | $1.77 | $2.74 | +23% | Bullish | |
| $1.21 | $1.77 | $2.80 | +23% | Bullish | |
| $1.45 | $2.16 | $3.49 | +50% | Bullish | |
| $1.57 | $2.39 | $3.93 | +66% | Bullish | |
| $1.57 | $2.44 | $4.08 | +69% | Bullish | |
| $1.83 | $3.10 | $5.57 | +115% | Bullish | |
| $2.26 | $4.45 | $8.85 | +209% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.38 | $1.44 | $1.81 | +0.00% |
| September 2026 | $1.25 | $1.48 | $1.82 | +2.95% |
| October 2026 | $1.21 | $1.45 | $1.80 | -2.26% |
| November 2026 | $1.24 | $1.50 | $1.89 | +3.71% |
| December 2026 | $1.26 | $1.53 | $1.94 | +1.76% |
Click any year to see its month-by-month GRI forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, GRI could reach as high as $1.94, with a base case around $1.44 and support toward $1.38 — roughly 0% from $1.44. A consolidation phase looks the most probable path here.
Expect GRI to range from $1.28 to $2.22 through 2027. The $1.63 average target implies a +13% move from current prices. That is up +13% on the projected 2026 average. Price action looks broadly range-bound.
The GRI price prediction for 2028 points to an average of $1.98 (low $1.50, high $2.82) — a potential gain of +38% on today's $1.44. Buyers look set to stay in control over this stretch.
In 2029, GRI is projected to trade between $1.45 and $2.91, averaging $1.98 — a potential gain of +37% from today's $1.44. That is 0% versus the projected 2028 average. Momentum favours further upside here.
GRI Bio, Inc.'s 2030 outlook centres on $1.90, within a $1.36 to $2.88 range. That is -4% versus the projected 2029 average. That marks a +32% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, GRI could reach as high as $2.74, with a base case around $1.77 and support toward $1.23 — roughly +23% from $1.44. Momentum favours further upside here.
Expect GRI to range from $1.21 to $2.80 through 2032. The $1.77 average target implies a +23% move from current prices. That is up 0% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The GRI price prediction for 2033 points to an average of $2.16 (low $1.45, high $3.49) — a potential gain of +50% on today's $1.44. Momentum favours further upside here.
In 2034, GRI is projected to trade between $1.57 and $3.93, averaging $2.39 — a potential gain of +66% from today's $1.44. That is up +11% on the projected 2033 average. Buyers look set to stay in control over this stretch.
GRI Bio, Inc.'s 2035 outlook centres on $2.44, within a $1.57 to $4.08 range. That is up +2% on the projected 2034 average. That marks a +69% change versus current levels. Momentum favours further upside here.
By 2040, GRI could reach as high as $5.57, with a base case around $3.10 and support toward $1.83 — roughly +115% from $1.44. Buyers look set to stay in control over this stretch.
Expect GRI to range from $2.26 to $8.85 through 2050. The $4.45 average target implies a +209% move from current prices. That is up +44% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in GRI today (≈ 694.444444 GRI) could be worth
$3,092.23
+$2,092.23 (+209%) by 2050 · US Dollar
Based on the average projected GRI price of $4.45 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in GRIwould be worth at today's price.
$1,000 invested in GRI on Jul 31, 2025 (≈ 27.901786 GRI) would be worth
$40.18
-$959.82 (-96.0%) today · 0.04× · US Dollar
Based on a GRI entry price of $35.84 vs. today's $1.44.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.45 | $993.1 | -0.7% |
| 1 month ago | $1.78 | $808.99 | -19.1% |
| 3 months ago | $2.18 | $660.55 | -33.9% |
| 6 months ago | $2.86 | $503.5 | -49.7% |
| 1 year ago | $35.84 | $40.18 | -96.0% |
| All time (5.0y) ago | $5,834,665 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our GRI forecast.
Our base-case forecast reaches $2.90 around 2040.
Implied market cap at $2.90: $5.14M
Multi-year forecasts show a bullish drift after 2026, with annualized price activity trending higher into 2050. The 2026 forecast is $1.40 (min), $1.40 (avg), $1.90 (max) with 0% ROI and NEUTRAL sentiment. From 2027 onward, the avg price rises to $1.60, $2.01 in 2028, then $1.97 in 2029, $1.87 in 2030, $1.75 in 2031, and $1.72 in 2032, all with bullish or neutral signals and ROIs ranging from 14.2% to 22.8%.
By 2033 the avg price jumps to $2.15 with a max of $3.58 and a 53.6% ROI, followed by $2.41 (avg) with a max of $4.09 and 72.2% ROI in 2034, and $2.40 (avg) with a max of $4.15 and 71.5% ROI in 2035. The trajectory strengthens toward 2040, where the avg price is $3.13 with a max of $5.83 and a 123.5% ROI, and culminates in 2050 with an avg of $4.33, a max of $8.98 and a 209.1% ROI, all under bullish sentiment.
These figures are estimates, not guarantees, and are accompanied by notable volatility (annualized volatility of 70%).
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $1.87 with a min of $1.31 and a max of $2.89, and a 33.4% ROI; sentiment is BULLISH.
The yearly forecasts trend from neutral in 2026–2027 to bullish later years, with an avg price rising to $4.33 by 2050 and ROIs up to 209.1%; however, 2026 shows 0% ROI and NEUTRAL sentiment, and these are estimates, not guarantees.
Yes. The forecast shows a 2034 max of $4.09 and a 2035 max of $4.15, with the 2040 max at $5.83 and the 2050 max at $8.98.
Current price is $1.40 and market capitalization is $2.48M.
The 30-day range is $1.10 to $1.78.
GRI Bio, Inc. Community Discussion
0Share your GRI Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.